Administration of PYY 3-36 also results in improved glucose control, improved lipid metabolism, and diminished insulin resistance in rodent models 1,38,41
These include mitigation of hyperglycemia, overweight and insulin resistance, systemic and glomerular hypertension, dyslipidemia, sodium retention, inflammation and renal hypoxia
Davidson M (2008) A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome
( J and K ) Attenuation of the body weightreducing effects of chronic systemic liraglutide during a standard chow ( J ) or high-fat food (HFF) diet ( K ) following GLP-1R knockdown in the dLS
[2] [5] They mimic the action of naturally occurring GLP-1, a hormone produced in the intestine that plays a crucial role in regulating blood glucose levels and appetite
This flexible approach respects the unpredictable nature of lupus while maintaining forward progress